InvestSMART

Syntara Limited (ASX: SNT) - Announcements

Current share price for SNT : $0.022 0.001 (2.22%)+

ASX company news and announcements for Syntara Limited (SNT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Syntara Limited (SNT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Syntara Limited (SNT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Syntara Limited (SNT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$43 Investor Presentation E&P Small Cap Healthcare Conference 9 Sep 2025 8:27AM $0.024 $0.022 fallen by 8.33%
$43 Letter to shareholders - path forward for amsulostat 1 Sep 2025 8:43AM $0.027 $0.022 fallen by 18.52%
$43 2025 Corporate Governance Statement 28 Aug 2025 2:23PM $0.027 $0.022 fallen by 18.52%
$43 Appendix 4G Key to Disclosures 28 Aug 2025 2:21PM $0.027 $0.022 fallen by 18.52%
$43 Annual Report to shareholders 28 Aug 2025 2:05PM $0.027 $0.022 fallen by 18.52%
$43 Preliminary Final Report 28 Aug 2025 1:55PM $0.027 $0.022 fallen by 18.52%
$43 Application for quotation of securities - SNT 28 Aug 2025 10:32AM $0.027 $0.022 fallen by 18.52%
$43 TechKnow Investor Presentation 19 Aug 2025 11:50AM $0.026 $0.022 fallen by 15.38%
$43 FDA guidance webinar 11 Aug 2025 9:51AM $0.057 $0.022 fallen by 61.40%
$43 Guidance from FDA on amsulostat clinical progression 11 Aug 2025 9:49AM $0.057 $0.022 fallen by 61.40%
$43 Application for quotation of securities - SNT 8 Aug 2025 8:33AM $0.057 $0.022 fallen by 61.40%
$43 Reinstatement to Quotation 4 Aug 2025 9:39AM $0.060 $0.022 fallen by 63.33%
$43 Proposed issue of securities to the CEO 4 Aug 2025 8:39AM $0.060 $0.022 fallen by 63.33%
$43 Notification regarding unquoted securities - SNT 4 Aug 2025 8:37AM $0.060 $0.022 fallen by 63.33%
$43 Quarterly update webinar presentation 1 Aug 2025 10:33AM $0.060 $0.022 fallen by 63.33%
$43 Suspension from Quotation 1 Aug 2025 9:30AM $0.060 $0.022 fallen by 63.33%
$43 Appendix 4C quarterly webinar 1 Aug 2025 9:01AM $0.060 $0.022 fallen by 63.33%
$43 Quarterly Appendix 4C Cash Flow Report 1 Aug 2025 8:17AM $0.060 $0.022 fallen by 63.33%
$43 Application for quotation of securities - SNT 30 Jul 2025 1:23PM $0.063 $0.022 fallen by 65.08%
$43 Quarterly Shareholder Report 30 Jul 2025 9:47AM $0.060 $0.022 fallen by 63.33%
$43 First participant dosed in SNT-9465 Phase 1a/b trial 29 Jul 2025 9:37AM $0.057 $0.022 fallen by 61.40%
$43 Initiation of Phase 1b/2 AZALOX clinical trial of amsulostat 18 Jul 2025 8:28AM $0.054 $0.022 fallen by 59.26%
$43 First patient dosed in SATELLITE Phase 1c for keloid scars 15 Jul 2025 9:26AM $0.048 $0.022 fallen by 54.17%
$43 WHO grants official INN for SNT-5505 - amsulostat 8 Jul 2025 8:26AM $0.050 $0.022 fallen by 56%
$43 Proposed issue of securities to the CEO 2 Jul 2025 11:20AM $0.051 $0.022 fallen by 56.86%

76 - 100 of 267 results

Page 4 of 11

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.